• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Development of in vitro and in vivo Systems for the Evaluation of Products for the Prevention and Detection of Hepatitis B, C and Dengue Viruses in the Blood Supply

Principal Investigator: Deborah R. Taylor, PhD
Office / Division / Lab: OBRR / DETTD / LEP


General Overview

The aim of our work is to help to prepare the U.S. for the possibility of future infectious disease outbreaks, either from natural disease emergence or from accidental or intentional (bioterrorism) release. Our laboratory is developing new methods and reagents, enabling us to learn more about the detection, pathogenesis and control of hepatitis viruses and emerging coronaviruses.

Hepatitis C (HCV) virus currently infects ~2% of the world's population. HCV chronically infects nearly everyone who is exposed to the virus, causing liver disease that can lead to liver failure and liver cancer and HCV is the leading cause of liver transplant in the US. There is no vaccine for HCV and treatment for the disease is ineffective, expensive, and causes severe side effects.

Because blood collection facilities use tests to screen for HCV, there are very few cases of transfusion-related transmission. However, the virus still poses a potential threat to the blood supply because it is an RNA virus. RNA viruses mutate frequently and many of the resulting, changed viruses survive and expand their numbers, making it difficult for existing tests to "recognize" them. Thus, these variants may escape detection. We are currently developing new techniques to grow strains of HCV and develop highly sensitive tests that can detect its presence.

Hepatitis-B (HBV), Hepatitis-C (HCV), and Hepatitis-E (HEV) viruses are blood-borne pathogens that infect millions of people world-wide, thereby creating a national and global public health burden. We designed a multiplex isothermal amplification-assay for simultaneous detection and fluorogenic differentiation of HBV, HCV, and HEV in blood-samples. The assay was performed in 60 minutes and can quantitate viral load. Preliminary results demonstrated detection sensitivity and revealed distinctive fluorogenic colors for each virus. The test is potentially applicable in blood-donor screening and diagnosis of viral infections, and is appropriate for resource-limited settings.

Dengue is a mosquito-borne virus and the most common vector-borne virus worldwide. More than 2.5 billion people are at risk for acquiring dengue. The incidence of dengue has increased in North America and Puerto Rico in recent years and threatens the U.S. blood supply. Our laboratory is growing dengue virus and studying features of the virus that affect its pathogenesis in order to develop and evaluate diagnostic and blood screening assays.

SARS coronavirus cause severe respiratory problems and is fatal in 10% of cases. The virus can spread quickly: it was first reported in China in the winter of 2002-2003 and by July had spread to 29 countries, having infected more than 8,000 people and leaving 774 people dead. We developed techniques for quantitating the virus and its infectivity and created reagents that will be useful should SARS emerge again. A new coronavirus is now known as the Middle Eastern Respiratory Syndrome or MERS-CoV. It is similar to SARS-CoV and has a high fatality rate (greater than 50%). At this time we are keeping an eye on the emerging epidemic and are concerned with the possibility that the virus may have the ability to be transmitted in blood.


Scientific Overview

Our laboratory work has two aims: the first is to develop proficiency panels and reference standards for emerging hepatitis viruses, for the purpose of assay development and lot release, to be provided to sponsors in the development of blood screening assays; and second, on improving the understanding of how viruses interact with host cells. This information will enable researchers to develop improved therapies that serve to control virus infection. We are trying to understand how viruses evade the innate immune system and how they regulate their own replication in the presence of the host antiviral response.

Standards Development: We are in the process of developing reference panels for HCV genotypes and for HEV. There are no CBER genotype panels and the ability to make these panels is limited by the inability for HCV to grow in cell culture.

HCV: The HCV field has been hampered by the lack of an in vitro cell culture system for growth of the virus. Recently, a system was developed using a recombinant form of an unusual strain of the virus. This is not the most drug-resistant of HCV strains and does not respond to antiviral therapeutics as expected for this strain. Our program has established a cell culture system for growing infectious hepatitis C virus (HCV) from human blood in culture. This system will enable the growth of viruses that can be used in vaccine preparations, and for the study of viral pathogenesis, growing viruses for use as panel members, the development of pathogen inactivation methods, and detecting products contaminated with HCV.

Dengue: Our laboratory is using a mouse model of dengue virus infection that may be used to test vaccinogens and evaluate correlates of immunity. This includes the study of innate immune pathways in control of dengue viruses in the infected host.

Coronaviruses: Virus studies have included serological and nucleic acid detection of virus and characterization of several techniques for inactivating SARS-CoV, including techniques to inactivate virus in blood products, such as UV inactivation and pasteurization. We study the replication of the SARS virus and its novel ribosome binding structure in order to understand viral pathogenesis and test potential antiviral therapeutics.


Publications

Viral Immunol 2013 Apr;26(2):126-32
Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates.
Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R

Nucleic Acids Res 2013 Feb 1;41(4):2594-608
RNA dimerization plays a role in ribosomal frameshifting of the SARS coronavirus.
Ishimaru D, Plant EP, Sims AC, Yount BL Jr, Roth BM, Eldho NV, Pérez-Alvarado GC, Armbruster DW, Baric RS, Dinman JD, Taylor DR, Hennig M

Viruses 2013 Jan 18;5(1):279-94
Altering SARS coronavirus frameshift efficiency affects genomic and subgenomic RNA production.
Plant EP, Sims AC, Baric RS, Dinman JD, Taylor DR

Arch Virol 2012 Nov;157(11):2095-104
Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates.
Ahn DG, Choi JK, Taylor DR, Oh JW

Vox Sang 2012 Aug;103(2):99-106
Distribution of hepatitis C virus in circulating blood components from blood donors.
Chancey C, Winkelman V, Foley JB, Silberstein E, Teixeira-Carvalho A, Taylor DR, Rios M

Antiviral Res 2011 Jul;91(1):1-10
Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication.
Ahn DG, Lee W, Choi JK, Kim SJ, Plant EP, Almazán F, Taylor DR, Enjuanes L, Oh JW

J Virol 2010 May;84(9):4330-40
Achieving a Golden Mean: Mechanisms by Which Coronaviruses Ensure Synthesis of the Correct Stoichiometric Ratios of Viral Proteins.
Plant EP, Rakauskaite R, Taylor DR, Dinman JD

PLoS Pathog 2010 May 20;6(5):e1000910
Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture.
Silberstein E, Mihalik K, Ulitzky L, Plant EP, Puig M, Gagneten S, Yu MY, Kaushik-Basu N, Feinstone SM, Taylor DR

Antivir Chem Chemother 2009 Sep 25;20(1):19-36
Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor.
Chen Y, Bopda-Waffo A, Basu A, Krishnan R, Silberstein E, Taylor DR, Talele TT, Arora P, Kaushik-Basu N

Front Biosci 2009 Jun 1;14:4950-61
Innate immunity and hepatitis C virus: eluding the host cell defense.
Taylor DR, Silberstein E

Front Biosci 2008 May 1;13:4873-81
The role of programmed-1 ribosomal frameshifting in coronavirus propagation.
Plant EP, Dinman JD

J Infect Dis 2007 Nov 1;196(9):1329-38
Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets.
Darnell ME, Plant EP, Watanabe H, Byrum R, St Claire M, Ward JM, Taylor DR

Transfusion 2006 Oct;46(10):1770-7
Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products.
Darnell ME, Taylor DR

Vaccine 2006 Feb 13;24(7):863-71
Obstacles and advances in SARS vaccine development.
Taylor DR

J Virol 2005 May;79(10):6291-8
New Antiviral Pathway That Mediates Hepatitis C Virus Replicon Interferon Sensitivity through ADAR1.
Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM

J Virol Methods 2004 Oct;121(1):85-91
Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV.
Darnell ME, Subbarao K, Feinstone SM, Taylor DR

J Virol 2004 Sep;78(18):9782-9
Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino Acid substitution rate and low levels of heterogeneity.
Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, Rice CM, Feinstone SM, Major ME

 
-
     
 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002